We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+32.17%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.01B
AUM Growth
+$300M
Cap. Flow
-$394M
Cap. Flow %
-7.86%
Top 10 Hldgs %
36.48%
Holding
142
New
15
Increased
17
Reduced
27
Closed
32

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$105M
2
BIIB icon
Biogen
BIIB
+$66.5M
3
ELV icon
Elevance Health
ELV
+$65.4M
4
SRRK icon
Scholar Rock
SRRK
+$27.5M
5
ARGX icon
argenx
ARGX
+$24.2M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$115M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$85.3M
3
BAX icon
Baxter International
BAX
+$84.5M
4
CI icon
Cigna
CI
+$66.2M
5
ABBV icon
AbbVie
ABBV
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Industrials 1.01%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCPH
51
DELISTED
scPharmaceuticals
SCPH
$34.9M 0.7%
5,559,528
– –
ARGX icon
52
argenx
ARGX
$55.1B
$32.2M 0.64%
84,600
+52,000
+160% +$24.2M
FUSN
53
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$30M 0.6%
3,122,770
– –
SLRN
54
DELISTED
ACELYRIN
SLRN
$29.9M 0.6%
4,001,711
-1,324,591
-25% -$11.3M
NMRA icon
55
Neumora Therapeutics
NMRA
$311M
$25.6M 0.51%
1,500,000
– –
XENE icon
56
Xenon Pharmaceuticals
XENE
$6.23B
$25.3M 0.51%
550,000
-408,793
-43% -$14.4M
RYTM icon
57
Rhythm Pharmaceuticals
RYTM
$7.36B
$24.7M 0.49%
536,642
-47,000
-8% -$1.48M
RPTX
58
DELISTED
Repare Therapeutics
RPTX
$24.3M 0.48%
3,322,488
– –
ABCL icon
59
AbCellera Biologics
ABCL
$1.67B
$23.9M 0.48%
4,180,768
– –
VERA icon
60
Vera Therapeutics
VERA
$2.33B
$23.3M 0.47%
1,518,115
– –
PMVP icon
61
PMV Pharmaceuticals
PMVP
$57.6M
$20.1M 0.4%
6,475,291
-87,786
-1% -$232K
KNTE
62
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$19M 0.38%
8,009,729
– –
TELA icon
63
TELA Bio
TELA
$30.4M
$18.8M 0.37%
2,835,542
– –
JBIO
64
Jade Biosciences
JBIO
$1.19B
$17.1M 0.34%
21,627
– –
IVVD icon
65
Invivyd
IVVD
$171M
$16.3M 0.32%
4,127,565
-1,142,835
-22% -$2.16M
IMTX icon
66
Immatics
IMTX
$1.19B
$16.3M 0.32%
1,543,407
+493,207
+47% +$4.54M
ACET icon
67
Adicet Bio
ACET
$76.7M
$15.7M 0.31%
520,134
– –
ALNY icon
68
Alnylam Pharmaceuticals
ALNY
$38.4B
$15.2M 0.3%
+79,400
New +$13.5M
PFE icon
69
CALL
Pfizer
PFE
$144B
$14.4M 0.29%
+500,000
New +$15.1M
KRYS icon
70
Krystal Biotech
KRYS
$10.7B
$12.9M 0.26%
+103,700
New +$11.5M
VSTM icon
71
Verastem
VSTM
$534M
$12.4M 0.25%
1,529,115
– –
CRVS icon
72
Corvus Pharmaceuticals
CRVS
$1.11B
$12.2M 0.24%
6,943,654
– –
REGN icon
73
Regeneron Pharmaceuticals
REGN
$73.1B
$11.9M 0.24%
13,500
– –
FOLD
74
DELISTED
Amicus Therapeutics
FOLD
$11.4M 0.23%
+806,000
New +$9.15M
PASG icon
75
Passage Bio
PASG
$14.9M
$10.2M 0.2%
506,229
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2023 Portfolio in Review

As of Q4 2023, OrbiMed held 142 positions worth $5.01B, up 6.4% from $4.71B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed withdrew a net $394M in Q4 2023, closing 32 positions and reducing 27 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, OrbiMed opened a new position in Elevance Health worth $66.7M.

  • OrbiMed's largest Q4 2023 buy was Elevance Health: 141,500 shares worth $66.7M.
  • OrbiMed added most to Eli Lilly in Q4 2023, an estimated $105M increase.
  • OrbiMed's biggest Q4 2023 reduction was Humana, cutting an estimated $115M.
  • OrbiMed fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $85.3M.
  • OrbiMed's ten largest holdings make up 36% of its $5.01B portfolio in Q4 2023.
  • OrbiMed opened 15 new positions and closed 32 in Q4 2023.
  • OrbiMed's portfolio value rose 6.4% quarter-over-quarter to $5.01B.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.